Small Cell Lung Cancer

The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.

Latest News

Digitally generated lungs held by doctor | Image credit: Image credit: PRASANNAPIX - stock.adobe.com
Chemo Plus IO Offers Survival Benefit in ES-SCLC vs Chemo Alone in Real-World Study

April 29th 2025

Combining immunotherapy with chemotherapy shows promise in enhancing survival rates for extensive-stage small cell lung cancer (ES-SCLC).

Considering the life-threatening risk of TLS, the researchers underscored the importance of identifying patients at particular risk of the complication. | Image credit: mi_viri - stock.adobe.com
Optimized Strategies Needed for TLS Prevention, Intervention in SCLC

April 23rd 2025

OS was the primary end point in the trial, and data from the planned interim analysis will be presented at an upcoming scientific meeting. | Image credit: Crystal light - stock.adobe.com
Tarlatamab Improves Overall Survival in Extensive-Stage SCLC

April 14th 2025

The new study suggests LTF should be considered as a potential biomarker of first-line treatment response in patients with ES-SCLC. | Image credit: appledesign - stock.adobe.com
Baseline LTF Linked With Treatment Response in SCLC

April 8th 2025

Doctor showing patient x-ray of lung cancer. | Image credit: Nattakorn – stock.adobe.com
3 DDR Phenotypes May Predict Chemotherapy Response in SCLC

March 25th 2025

Multidisciplinary Approaches to Paraneoplastic LEMS

Hear from medical experts as they explore the connection between Lambert-Eaton myasthenic syndrome and small cell lung cancer, discussing diagnostic challenges, economic impacts, and strategies for optimizing care.

Hear from medical experts as they explore the connection between Lambert-Eaton myasthenic syndrome and small cell lung cancer, discussing diagnostic challenges, economic impacts, and strategies for optimizing care.

More News

OneOncology’s NGS Testing Abstracts Accepted for Oral Presentation at ASCO 2023
May 24th 2023

OneOncology’s NGS Testing Abstracts Accepted for Oral Presentation at ASCO 2023

Thomas Stricker, MD, PhD, and Gregory Vidal, MD, PhD, are both first authors on their respective abstracts involving patients with advanced non-small cell lung cancer in the community setting.
Doctor, woman with tablet in hands and hologram with medical data, anatomy and lung x ray with overlay. Technology research in healthcare, futuristic and analytics with person and wireless tech: © peopleimages.com - stock.adobe.com
May 22nd 2023

Study Assesses Cost Differences for Robot- vs Video-Assisted Thoracoscopic Surgery in Lung Cancer

Gianna Melillo
Researchers took both the learning curve of the new process and the COVID-19 pandemic into consideration.
Site Logo
May 18th 2023

Better Together? Costs of First-line Chemoimmunotherapy for Advanced Non–Small Cell Lung Cancer

Jonathan Kish, PhD, MPH Djibril Liassou, MS John Hartman, PhD Solomon J. Lubinga, PhD Dhruv Chopra, MS Bruce Feinberg, DO
Compared with first-line immunotherapy or chemotherapy alone, combination chemoimmunotherapy for advanced/metastatic non–small cell lung cancer has significantly higher antineoplastic drug and associated medical costs.
Osimertinib Plus Chemotherapy Improves PFS vs Osimertinib Alone in EGFRm NSCLC
May 17th 2023

Osimertinib Plus Chemotherapy Improves PFS vs Osimertinib Alone in EGFRm NSCLC

Rose McNulty
Osimertinib plus chemotherapy showed a statistically significant improvement in progression-free survival (PFS) vs osimertinib alone in patients with epidermal growth factor receptor–mutated (EGFRm) advanced non–small cell lung cancer (NSCLC)
Human Lung model illness, Lung cancer and lung disease. Generative AI: © Royalty-Free - stock.adobe.com
May 16th 2023

Study Examines Incidence, Risk Factors for ICI-Related Pneumonitis in NSCLC

Gianna Melillo
Immune checkpoint inhibitors (ICIs) can increase life expectancy among patients who have non–small cell lung cancer (NSCLC), but they also carry the risk of immune-related adverse events.
Happiness group of people huddle and smiling together: © Rawpixel.com - stock.adobe.com
May 11th 2023

Patients With Advanced Lung Cancer Prioritize Social, Relational Goals Above Treatment Outcomes

Jared Kaltwasser
Just 29% of patients listed a treatment-response goal among their top personal goals.
Chemotherapy Plus Cemiplimab Improves QOL vs Chemotherapy Alone in NSCLC
May 9th 2023

Chemotherapy Plus Cemiplimab Improves QOL vs Chemotherapy Alone in NSCLC

Rose McNulty
An analysis of the EMPOWER‐Lung 3 trial found that the addition of cemiplimab to platinum chemotherapy for non­–small cell lung cancer (NSCLC) was associated with improved patient quality of life (QOL) vs chemotherapy alone.
For Treatment Resistance in NSCLC, Repeat Biomarker Testing Is Key, Says Dr Mark Socinski
May 4th 2023

For Treatment Resistance in NSCLC, Repeat Biomarker Testing Is Key, Says Dr Mark Socinski

Rose McNulty
Mark A. Socinski, MD, executive director of AdventHealth Cancer Institute, gave insight into treatment resistance and the importance of repeat biomarker testing at the time of disease progression in non–small cell lung cancer (NSCLC).
AJMC
May 1st 2023

Factors Associated With Lung Cancer Risk Factor Documentation

Leah M. Marcotte, MD, MS Sara Khor, MASc David R. Flum, MD, MPH Nkem Akinsoto, MSc Vandna Chaudhari, MHA Douglas E. Wood, MD Danielle C. Lavallee, PharmD, PhD Matthew Triplette, MD, MPH Farhood Farjah, MD, MPH
This cross-sectional observational study found several factors associated with whether a patient had sufficient lung cancer risk factor documentation in the electronic health record.
Liquid and Tissue Biopsy Can Be Complementary in NSCLC, Says Dr Mark Socinski
April 29th 2023

Liquid and Tissue Biopsy Can Be Complementary in NSCLC, Says Dr Mark Socinski

Rose McNulty
Mark A. Socinski, MD, executive director of the AdventHealth Cancer Institute, shares his insight on liquid- and tissue-based biopsies and their clinical utility in non–small cell lung cancer (NSCLC).
ASTRO, ESTRO Release First Guideline for Definitive Local Therapy in Oligometastatic NSCLC
April 27th 2023

ASTRO, ESTRO Release First Guideline for Definitive Local Therapy in Oligometastatic NSCLC

Rose McNulty
The American Society for Radiation Oncology (ASTRO) and European Society for Radiotherapy and Oncology (ESTRO) jointly released a clinical guideline on the use of definitive local therapy for the treatment of oligometastatic non–small cell lung cancer (NSCLC).
Libtayo
April 21st 2023

Dr Tamta Makharadze Discusses EMPOWER-Lung 3 Data for Frontline Cemiplimab Plus Chemo in Advanced NSCLC

Interview by Mary Caffrey
Final overall survival data were presented at the European Lung Cancer Congress in Copenhagen, Denmark.
CancerCare Tool Kit Aims to Guide Employers in Biomarker Coverage Decisions
April 17th 2023

CancerCare Tool Kit Aims to Guide Employers in Biomarker Coverage Decisions

Interview by Mary Caffrey
Evidence-Based Oncology (EBO) spoke with Len Lichtenfeld, MD, the chief medical officer for Jasper Health and a board member with CancerCare.
Long-Term Benefits of Cemiplimab Plus Chemotherapy Seen in Locally Advanced NSCLC
April 15th 2023

Long-Term Benefits of Cemiplimab Plus Chemotherapy Seen in Locally Advanced NSCLC

Conor Killmurray Rose McNulty
A post-hoc analysis of the EMPOWER-Lung 1 and 3 studies demonstrates long-term survival and responses for patients with locally advanced non–small-cell lung cancer (NSCLC) treated with cemiplimab.
Estimated Lung Cancer Screening Rates "Extremely Low" Across Insurance Types
April 14th 2023

Estimated Lung Cancer Screening Rates "Extremely Low" Across Insurance Types

Rose McNulty
Estimated rates of lung cancer screening with low-dose CT were extremely low among eligible patients across insurance types in 2017, with rates varying between patient demographics.
Sublobar Resection Produces Similar Outcomes to Lobectomy in Early NSCLC
April 5th 2023

Sublobar Resection Produces Similar Outcomes to Lobectomy in Early NSCLC

Rose McNulty
Patients who underwent sublobar resection and those who underwent more invasive lobectomy for early-stage non–small cell lung cancer (NSCLC) showed similar overall and disease-free survival outcomes in a recent study.
Davey B. Daniel, MD, chief medical officer, OneOncology
April 4th 2023

Dr Davey Daniel on the Importance of Biomarker Tests for Patients With Lung Cancer

Pearl Steinzor
Biomarker testing is a key tool in lung cancer treatment, and Kentucky recently passed a law requiring payers to cover biomarker tests with the intention to address high rates of lung cancer in the state.
Patient taking survey
March 31st 2023

Quality of Life at Diagnosis Predicts Survival in Patients With Lung Cancer

Rose McNulty
Assessing both physical and emotional functioning scales within cancer quality-of-life questionnaires at diagnosis may help predict survival in patients with lung cancer, a recent study found.
Lungs
March 30th 2023

Immunotherapy for NSCLC Safe in Elderly Patients, but More Research Needed

Rose McNulty
A review based on an expert panel discussion highlights a need for the inclusion of older patients in studies of immune checkpoint inhibitors for the first-line treatment of advanced non–small cell lung cancer (NSCLC).
Surgical room
March 24th 2023

Neoadjuvant Therapy Does Not Increase Morbidity Post Sleeve Lobectomy in NSCLC

Rose McNulty
A recent study suggests that sleeve lobectomy is safe to perform in patients with non–small cell lung cancer who received neoadjuvant therapy.
Lungs
March 22nd 2023

Study Shows Varied Immunotherapy Benefits Among Younger and Older Patients With NSCLC

Rose McNulty
The survival benefits of immune checkpoint inhibitors varied in young patients versus older patients with advanced non–small-cell lung cancer, a recent study found.
Biopsy Method, Needle Size Impacts NGS Success Rates in Lung Cancer
March 17th 2023

Biopsy Method, Needle Size Impacts NGS Success Rates in Lung Cancer

Rose McNulty
Different methods of DNA collection and needle sizes led to varied next-generation sequencing success rates among patients with lung cancer in a recent study.
Network of patients
March 15th 2023

Racial, Ethnic, Socioeconomic Disparities Identified Among Patients With Cachexia at NSCLC Diagnosis

Rose McNulty
A recent study identified disparities in cachexia incidence among patients with stage IV non–small cell lung cancer (NSCLC) across different racial, ethnic, and socioeconomic groups.
FDA
March 8th 2023

FDA Expands Approval for Companion Diagnostic for Cemiplimab in NSCLC

Chris Ryan
The FDA approved the VENTANA PD-L1 assay for expanded use in patients with advanced non–small-cell lung cancer to help identify patients who may be candidates for treatment with cemiplimab.
Annual Lung Cancer Screening Adherence Poor After Initial Screening, Study Finds
March 4th 2023

Annual Lung Cancer Screening Adherence Poor After Initial Screening, Study Finds

Rose McNulty
Adherence to annual lung cancer screening was only 22.3% among more than 1 million patients who underwent baseline screening between 2015 and 2019, a study published in the journal CHEST found.
Composite image of lungs and a doctor
March 2nd 2023

Cemiplimab Plus Chemotherapy Approaches EU Approval for PD-L1–Positive NSCLC

Kristi Rosa
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of cemiplimab-rwlc in combination with platinum-based chemotherapy as frontline treatment for adult patients with advanced non–small-cell lung cancer with PD-L1 expression of 1% or higher.
Image of genetic code with biomarker highlighted
February 23rd 2023

Study Identifies FGFR3 as Biomarker for Superior Outcomes in NSCLC

Jared Kaltwasser
Positive expression levels of the biomarker were more common in adenocarcinoma than in squamous cell carcinoma, among patients who had non–small cell lung cancer (NSCLC).
Image depicting genetic research
February 20th 2023

Immune Signature Could Help Tailor Treatment Choices in NSCLC

Jared Kaltwasser
The authors identified 2 subgroups with non–small cell lung cancer (NSCLC) who had different responses to common cancer therapies.
Image of a radiologist looking at a lung cancer image
February 16th 2023

Real-World Data Show SCLC Outcomes Remain Grim

Jared Kaltwasser
The authors say newer treatment options for small cell lung cancer (SCLC) may lead to improvement in this area of high unmet need.
Image of an oncologist pointing out lung cancer
February 13th 2023

Surgical Quality Metric Adherence Substantially Improves Outcomes in Early NSCLC

Jared Kaltwasser
Overall survival and recurrence-free survival showed substantial improvement when physicians more closely followed quality recommendations for non–small cell lung cancer (NSCLC).
<12345678
...
10>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo